Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Allegra, C. J.
Right arrow Articles by Wieand, H. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Allegra, C. J.
Right arrow Articles by Wieand, H. S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 21, Issue 2 (January), 2003: 241-250
© 2003 American Society for Clinical Oncology

Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients With Dukes’ B and C Colon Cancer: A National Cancer Institute–National Surgical Adjuvant Breast and Bowel Project Collaborative Study

Carmen J. Allegra, Soon Paik, Linda H. Colangelo, Allyson L. Parr, Ilan Kirsch, George Kim, Pamela Klein, Patrick G. Johnston, Norman Wolmark, H. Samuel Wieand

From the Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD; the National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA; and the Department of Oncology, Belfast City Hospital, Northern Ireland.

Address reprint requests to Carmen J. Allegra, MD, 31 Center Dr, MSC 2440, Bldg 31, Rm 3A-44, Bethesda, MD 20892-2440; email: allegrac{at}navmed.nci.nih.gov.

Purpose: To define the value of thymidylate synthase (TS), Ki-67, and p53 as prognostic markers in patients with stage II and III colon carcinoma.

Patients and Methods: We retrospectively analyzed the prognostic value of TS, Ki-67, and p53 in 706 patients with Dukes’ B (291 patients) or Dukes’ C (415 patients) colon carcinoma who were treated with either surgery alone (275 patients) or surgery plus fluorouracil (FU)-leucovorin chemotherapy (431 patients) in National Surgical Adjuvant Breast and Bowel Project (NSABP) protocols C01-C04. All three markers were assayed using immunohistochemical techniques.

Results: Using 5 years of follow-up data, our retrospective analysis demonstrated an association between TS intensity (relapse-free survival [RFS]: risk ratio [RR] = 1.46, P = .01; overall survival [OS]: RR = 1.54, P = .002), Ki-67 (RFS: RR = 0.76, P = .05; OS: RR = 0.62, P = .001), and p53 (RFS: RR = 1.49, P = .01; OS: RR = 1.21, P = .18) for RFS and OS. High TS intensity levels and positive p53 staining were associated with a worse outcome. Tumors containing a high percentage of Ki-67-positive cells enjoyed an improved outcome compared with those patients whose tumors contained relatively few positive cells. An interaction with treatment was not identified for any of the markers.

Conclusion: This retrospective investigation demonstrated that TS, Ki-67, and p53 staining each had significant prognostic value for patients with Dukes’ B and C colon carcinoma. However, none of the markers could be used to clearly discern groups of individuals who would be predicted to derive greater or lesser benefit from the use of adjuvant chemotherapy.

Supported by Public Health Service grants U10CA12027, U10CA69651, UC10CA37377, and U10CA69974 from the National Cancer Institute (NCI), National Institutes of Health, Department of Health and Human Services, Bethesda, MD. This investigation was conducted after approval by a local and NCI Institutional Review Board committee and in accord with an assurance filed with and approved by the Department of Health and Human Services.

An abstract of this information was presented at the 2001 meeting of the American Society of Clinical Oncology as "Prognostic Value of Thymidylate Synthase, Ki-67, and p53 in Patients with Dukes’ B and C Colon Cancer."


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. Zaanan, P. Cuilliere-Dartigues, A. Guilloux, Y. Parc, C. Louvet, A. de Gramont, E. Tiret, S. Dumont, B. Gayet, P. Validire, et al.
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin
Ann. Onc., October 15, 2009; (2009) mdp383v1.
[Abstract] [Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
L. R. Moreira, A. Almeida Schenka, P. Latuff Filho, H. Nascimento, C. S. Passos Lima, M. A. Silva Trevisan, and J. Vassallo
Correlation Between Thymidylate Synthase Protein Expression and Gene Polymorphism with Clinicopathological Parameters in Colorectal Carcinoma
International Journal of Surgical Pathology, June 1, 2009; 17(3): 181 - 186.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
R. Sato, T. Suzuki, Y. Katayose, K. Miura, K. Shiiba, H. Tateno, Y. Miki, J. Akahira, Y. Kamogawa, S. Nagasaki, et al.
Steroid Sulfatase and Estrogen Sulfotransferase in Colon Carcinoma: Regulators of Intratumoral Estrogen Concentrations and Potent Prognostic Factors
Cancer Res., February 1, 2009; 69(3): 914 - 922.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
G. E. THEODOROPOULOS, E. KARAFOKA, J. G. PAPAILIOU, P. STAMOPOULOS, C. P. ZAMBIRINIS, K. BRAMIS, S.-G. PANOUSSOPOULOS, E. LEANDROS, and J. BRAMIS
p53 and EGFR Expression in Colorectal Cancer: A Reappraisal of 'Old' Tissue Markers in Patients with Long Follow-up
Anticancer Res, February 1, 2009; 29(2): 785 - 791.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
I Zlobec and A Lugli
Prognostic and predictive factors in colorectal cancer
Postgrad. Med. J., August 1, 2008; 84(994): 403 - 411.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
B. Pasche
Familial Colorectal Cancer: A Genetics Treasure Trove for Medical Discovery
JAMA, June 4, 2008; 299(21): 2564 - 2565.
[Full Text] [PDF]

Home page
 JCOHome page
M. S. Braun, S. D. Richman, P. Quirke, C. Daly, J. W. Adlard, F. Elliott, J. H. Barrett, P. Selby, A. M. Meade, R. J. Stephens, et al.
Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial
J. Clin. Oncol., June 1, 2008; 26(16): 2690 - 2698.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
I Zlobec and A Lugli
Prognostic and predictive factors in colorectal cancer
J. Clin. Pathol., May 1, 2008; 61(5): 561 - 569.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-M. Hu and Z.-F. Chang
Synthetic Lethality by Lentiviral Short Hairpin RNA Silencing of Thymidylate Kinase and Doxorubicin in Colon Cancer Cells Regardless of the p53 Status
Cancer Res., April 15, 2008; 68(8): 2831 - 2840.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. Gill, A. W. Blackstock, and R. M. Goldberg
Colorectal Cancer
Mayo Clin. Proc., January 1, 2007; 82(1): 114 - 129.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Al-Mulla, S. Hagan, A. I. Behbehani, M. S. Bitar, S. S. George, J. J. Going, J. J. C. Garcia, L. Scott, N. Fyfe, G. I. Murray, et al.
Raf Kinase Inhibitor Protein Expression in a Survival Analysis of Colorectal Cancer Patients
J. Clin. Oncol., December 20, 2006; 24(36): 5672 - 5679.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S Popat, Z Chen, D Zhao, H Pan, N Hearle, I Chandler, Y Shao, W Aherne, and R. Houlston
A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer
Ann. Onc., December 1, 2006; 17(12): 1810 - 1817.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. Galle, D. Sittig, I. Hanisch, M. Wobus, E. Wandel, M. Loeffler, and G. Aust
Individual Cell-Based Models of Tumor-Environment Interactions: Multiple Effects of CD97 on Tumor Invasion
Am. J. Pathol., November 1, 2006; 169(5): 1802 - 1811.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. A. Sinicrope, R. L. Rego, K. C. Halling, N. R. Foster, D. J. Sargent, B. La Plant, A. J. French, C. J. Allegra, J. A. Laurie, R. M. Goldberg, et al.
Thymidylate synthase expression in colon carcinomas with microsatellite instability.
Clin. Cancer Res., May 1, 2006; 12(9): 2738 - 2744.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. Garcia, J. M. Garcia, C. Pena, J. Silva, G. Dominguez, A. Hurtado, I. Alonso, R. Rodriguez, M. Provencio, and F. Bonilla
Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential.
Clin. Cancer Res., April 1, 2006; 12(7): 2095 - 2100.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. M. Hoff
Is There a Role for Routine p53 Testing in Colorectal Cancer?
J. Clin. Oncol., October 20, 2005; 23(30): 7395 - 7396.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. J. Allegra and R. W. Childs
Cytotoxins and Cancer Immunotherapy: The Dance of the Macabre?
J Natl Cancer Inst, October 5, 2005; 97(19): 1396 - 1397.
[Full Text] [PDF]

Home page
 JCOHome page
K. Ohrling, D. Edler, M. Hallstrom, P. Ragnhammar, and H. Blomgren
Detection of Thymidylate Synthase Expression in Lymph Node Metastases of Colorectal Cancer Can Improve the Prognostic Information
J. Clin. Oncol., August 20, 2005; 23(24): 5628 - 5634.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Krajewska, H. Kim, C. Kim, H. Kang, K. Welsh, S.-i. Matsuzawa, M. Tsukamoto, R. G. Thomas, N. Assa-Munt, Z. Piao, et al.
Analysis of Apoptosis Protein Expression in Early-Stage Colorectal Cancer Suggests Opportunities for New Prognostic Biomarkers
Clin. Cancer Res., August 1, 2005; 11(15): 5451 - 5461.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. H. Frey, H. Alakus, J. Wohlschlaeger, K. J. Schmitz, G. Winde, H. G. van Calker, K.-H. Jockel, W. Siffert, and K. W. Schmid
GNAS1 T393C Polymorphism and Survival in Patients with Sporadic Colorectal Cancer
Clin. Cancer Res., July 15, 2005; 11(14): 5071 - 5077.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. L. Allen and P. G. Johnston
Role of Genomic Markers in Colorectal Cancer Treatment
J. Clin. Oncol., July 10, 2005; 23(20): 4545 - 4552.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
W. L. Ince, A. M. Jubb, S. N. Holden, E. B. Holmgren, P. Tobin, M. Sridhar, H. I. Hurwitz, F. Kabbinavar, W. F. Novotny, K. J. Hillan, et al.
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
J Natl Cancer Inst, July 6, 2005; 97(13): 981 - 989.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Ricciardiello, C. Ceccarelli, G. Angiolini, M. Pariali, P. Chieco, P. Paterini, G. Biasco, G. N. Martinelli, E. Roda, and F. Bazzoli
High Thymidylate Synthase Expression in Colorectal Cancer with Microsatellite Instability: Implications for Chemotherapeutic Strategies
Clin. Cancer Res., June 1, 2005; 11(11): 4234 - 4240.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. M. Ghadimi, M. Grade, M. J. Difilippantonio, S. Varma, R. Simon, C. Montagna, L. Fuzesi, C. Langer, H. Becker, T. Liersch, et al.
Effectiveness of Gene Expression Profiling for Response Prediction of Rectal Adenocarcinomas to Preoperative Chemoradiotherapy
J. Clin. Oncol., March 20, 2005; 23(9): 1826 - 1838.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Michael and M.M. Doherty
Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy
J. Clin. Oncol., January 1, 2005; 23(1): 205 - 229.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Ravi, A. J. Jain, R. D. Schulick, V. Pham, T. S. Prouser, H. Allen, E. G. Mayer, H. Yu, D. M. Pardoll, A. Ashkenazi, et al.
Elimination of Hepatic Metastases of Colon Cancer Cells via p53-Independent Cross-Talk between Irinotecan and Apo2 Ligand/TRAIL
Cancer Res., December 15, 2004; 64(24): 9105 - 9114.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. L. Eiseman, C. Brown-Proctor, P. E. Kinahan, J. M. Collins, L. W. Anderson, E. Joseph, D. R. Hamburger, S.-s. Pan, C. A. Mathis, M. J. Egorin, et al.
Distribution of 1-(2-Deoxy-2-fluoro-{beta}-D-arabinofuranosyl) Uracil in Mice Bearing Colorectal Cancer Xenografts: Rationale for Therapeutic Use and as a Positron Emission Tomography Probe for Thymidylate Synthase
Clin. Cancer Res., October 1, 2004; 10(19): 6669 - 6676.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Gill, C. L. Loprinzi, D. J. Sargent, S. D. Thome, S. R. Alberts, D. G. Haller, J. Benedetti, G. Francini, L. E. Shepherd, J. Francois Seitz, et al.
Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
J. Clin. Oncol., May 15, 2004; 22(10): 1797 - 1806.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Galizia, E. Lieto, F. Ferraraccio, M. Orditura, F. De Vita, P. Castellano, V. Imperatore, C. Romano, F. Ciardiello, B. Agostini, et al.
Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas
Clin. Cancer Res., May 15, 2004; 10(10): 3490 - 3499.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. G. Johnston
Of What Value Genomics in Colorectal Cancer? Opportunities and Challenges
J. Clin. Oncol., May 1, 2004; 22(9): 1538 - 1539.
[Full Text] [PDF]

Home page
 JCOHome page
M. M. Garrity, L. J. Burgart, M. R. Mahoney, H. E. Windschitl, M. Salim, M. Wiesenfeld, J. E. Krook, J. C. Michalak, R. M. Goldberg, M. J. O'Connell, et al.
Prognostic Value of Proliferation, Apoptosis, Defective DNA Mismatch Repair, and p53 Overexpression in Patients With Resected Dukes' B2 or C Colon Cancer: A North Central Cancer Treatment Group Study
J. Clin. Oncol., May 1, 2004; 22(9): 1572 - 1582.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. B. Resnick, J. Routhier, T. Konkin, E. Sabo, and V. E. Pricolo
Epidermal Growth Factor Receptor, c-MET, {beta}-Catenin, and p53 Expression as Prognostic Indicators in Stage II Colon Cancer: A Tissue Microarray Study
Clin. Cancer Res., May 1, 2004; 10(9): 3069 - 3075.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Popat, A. Matakidou, and R. S. Houlston
Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-Analysis
J. Clin. Oncol., February 1, 2004; 22(3): 529 - 536.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
D L Francis, A Freeman, D Visvikis, D C Costa, S K Luthra, M Novelli, I Taylor, and P J Ell
In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography
Gut, November 1, 2003; 52(11): 1602 - 1606.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. J. Allegra, G. Kim, I. R. Kirsch, B. Iacopetta, H. Elsaleh, N. Zeps, J. J. Jimenez, A. Blanes, S. J. Diaz-Cano, R. Gryfe, et al.
Microsatellite Instability in Colon Cancer
N. Engl. J. Med., October 30, 2003; 349(18): 1774 - 1776.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online